News | May 25, 2021
Bal Pharma launches BALflu, Favipiravir formulation in India
BALflu is approved by DCGI for emergency use for the treatment of COVID-19
BALflu is approved by DCGI for emergency use for the treatment of COVID-19
Availability of drugs is being monitored by implementing a three-pronged strategy of supply chain management, demand side management, and affordability.
Natco has withdrawn its application filed with the Indian Patent Office, seeking Compulsory License against Lilly for Baricitinib for Covid-19 in India
Favipiravir is close to Remdesivir, Remdesivir is used to treat moderate to severe cases while Favipiravir is used to treat mild to moderate cases
This achievement enables the company to strengthen its presence in the high growth market of South Asian countries
The company is pursuing specific goals in the areas of science and technology, value chain as well as climate and the environment.
The company has received a certificate of Good Manufacturing Practice compliance from the Medicines & Healthcare products Regulatory Agency (MHRA) UK
The receipt of this permission paves way for the launch of Osimertinib 40mg/80mg film coated tablets in India.
Nitazoxanide Tablets, 500 mg (RLD: Alinia) had estimated annual sales of USD 56 million in the U.S.
Vivimed strategy is to increase its share of Branded products in CIS Markets.
Subscribe To Our Newsletter & Stay Updated
